Backstrom Jay T.
Known title: CHIEF EXECUTIVE OFFICERCIK: 0001796398
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Transaction History
| AGIO | ▲ Buy | Grant | 1,447 | $0 | 7/8/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 113,570 | $0 | 3/10/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 18,372 | $677K | 2/18/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 22,308 | $986K | 1/16/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 11,614 | $183K | 2/16/2024 | View on chart |
| SRRK | ▲ Buy | Grant | 214,285 | $0 | 2/12/2024 | View on chart |
| SRRK | ▲ Buy | Grant | 150,000 | $0 | 2/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call
AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.